NCT00230334View on ClinicalTrials.gov

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

June 12, 2003

Primary Completion Date

December 29, 2006

Study Completion Date

May 31, 2007

Conditions

EosinophiliaHypereosinophilic Syndrome

Interventions

DRUG

Gleevec

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Steven E. Coutre

OTHER